Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shanu Modi

Showing results (111-120 of 115) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 115 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 28, 2020
Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I StudyKaren A Autio, Christopher A Klebanoff, David Schaer, et al.
Nature Cancer|September 1, 2020
Alterations in <i>PTEN</i> and <i>ESR1</i> promote clinical resistance to alpelisib plus aromatase inhibitorsPedram Razavi, Maura N Dickler, Payal D Shah, et al.
The New England Journal of Medicine|June 6, 2022
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast CancerShanu Modi, William Jacot, Toshinari Yamashita, et al.
Nature|October 6, 2016
The epichaperome is an integrated chaperome network that facilitates tumour survivalAnna Rodina, Tai Wang, Pengrong Yan, et al.
Cancer Cell|September 12, 2018
The Genomic Landscape of Endocrine-Resistant Advanced Breast CancersPedram Razavi, Matthew T Chang, Guotai Xu, et al.
Pageof 12

Showing results (111-120 of 115) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 115 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 28, 2020
Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I StudyKaren A Autio, Christopher A Klebanoff, David Schaer, et al.
Nature Cancer|September 1, 2020
Alterations in <i>PTEN</i> and <i>ESR1</i> promote clinical resistance to alpelisib plus aromatase inhibitorsPedram Razavi, Maura N Dickler, Payal D Shah, et al.
The New England Journal of Medicine|June 6, 2022
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast CancerShanu Modi, William Jacot, Toshinari Yamashita, et al.
Nature|October 6, 2016
The epichaperome is an integrated chaperome network that facilitates tumour survivalAnna Rodina, Tai Wang, Pengrong Yan, et al.
Cancer Cell|September 12, 2018
The Genomic Landscape of Endocrine-Resistant Advanced Breast CancersPedram Razavi, Matthew T Chang, Guotai Xu, et al.
Pageof 12